deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02419612

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin ≥1500 mg in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Sponsor: AstraZeneca

Conditions Diabetes
Updated 17 times since 2017 Last updated: Jun 22, 2020 Started: Aug 14, 2015 Primary completion: Aug 29, 2017 Completion: Sep 18, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 17 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jul 2020 · 7 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jul 2020 — Jan 2021 [monthly]

    Completed PHASE3

Show 12 earlier versions
  1. Dec 2019 — Jul 2020 [monthly]

    Completed PHASE3

  2. Nov 2019 — Dec 2019 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  3. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Feb 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Aug 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE3

  10. May 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE3

  11. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .